BRAIN Biotech AG Logo

BRAIN Biotech AG

BNN | F

Overview

Corporate Details

ISIN(s):
DE0005203947 (+1 more)
LEI:
391200JKPVHLD6JLZ107
Country:
Germany
Address:
Darmstädter Straße 34-36, 64673 Zwingenberg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

BRAIN Biotech AG is a leading European specialist in industrial biotechnology, focused on developing bio-based products and solutions. The company provides end-to-end services encompassing the discovery, development, and production of specialty enzymes, proteins, and microbial production strains. Through its contract research and development (R&D) model, BRAIN Biotech leverages an advanced technology portfolio to deliver tailor-made biosolutions for industrial clients, primarily in the food and life sciences sectors. These customized solutions help customers overcome complex scientific challenges, creating innovative and sustainable products and processes that enhance their commercial success and competitive market advantages.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for BRAIN Biotech AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-23 08:30
Board/Management Information
Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
English 13.4 KB
2025-06-23 08:05
Share Issue/Capital Change
Price range set: Brainlab targets a market capitalization of c. EUR 1.67 billio…
English 22.4 KB
2025-05-28 07:30
Earnings Release
BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25
English 20.0 KB
2025-05-28 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.10.2024 bis zum 31.03…
German 99.2 KB
2025-05-28 00:00
Interim Report
Half-yearly financial report 2024/2025
English 364.5 KB
2025-05-21 10:00
M&A Activity
BRAIN Biotech announces buy-out of minorities, new continental European product…
English 16.2 KB
2025-05-19 11:23
Report Publication Announcement
English 4.1 KB
2025-05-19 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.10.2024 bis zum 31.03.2025
German 5.8 KB
2025-05-19 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.10.2024 bis zum 31.03.2025
German 5.8 KB
2025-04-30 17:54
Earnings Release
BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservati…
English 6.0 KB
2025-03-19 16:45
Post-Annual General Meeting Information
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BR…
English 14.6 KB
2025-03-18 16:45
Post-Annual General Meeting Information
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BR…
English 14.6 KB
2025-03-04 11:25
Director's Dealing
BRAIN Biotech AG: Michael Schneiders, buy
English 6.0 KB
2025-03-03 11:25
Director's Dealing
BRAIN Biotech AG: Michael Schneiders, buy
English 6.0 KB
2025-02-27 07:30
Earnings Release
BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growt…
English 20.8 KB

Automate Your Workflow. Get a real-time feed of all BRAIN Biotech AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BRAIN Biotech AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-03 Schneiders, Michael Board Buy None 25,000.00 EUR
2025-01-16 Moelker, Adriaan Board Buy None 35,795.96 EUR

Peer Companies

Company Country Ticker View
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Theranexus Logo
Biopharma developing drug candidates for rare neurological diseases like Batten disease.
France ALTHX
TME Pharma N.V. Logo
Clinical-stage biotech developing TME-targeting therapies for aggressive cancers.
Germany ALTME
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
Transgene Logo
Clinical-stage biotech using viral vectors for cancer vaccines and oncolytic viruses.
France TNG
Tvardi Therapeutics Inc. Logo United States of America TVRD
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
Hong Kong N/A
Urteste S.A. Logo
Developing non-invasive urine tests for early detection & monitoring of multiple cancers.
Poland URT
VALIRX PLC Logo
Developing early-stage therapeutics & diagnostics for oncology and women's health.
United Kingdom VAL